Role for PP2A in ARF signaling to p53.

A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-induced dephosphorylation of p53 at Thr55. EMBO J (2007) 1.58

Lessons in signaling and tumorigenesis from polyomavirus middle T antigen. Microbiol Mol Biol Rev (2009) 1.48

p53 targets identified by protein expression profiling. Proc Natl Acad Sci U S A (2007) 1.23

Lessons from polyoma middle T antigen on signaling and transformation: A DNA tumor virus contribution to the war on cancer. Virology (2008) 1.20

Polyoma and SV40 proteins differentially regulate PP2A to activate distinct cellular signaling pathways involved in growth control. Proc Natl Acad Sci U S A (2006) 1.12

Small tumor antigen of polyomaviruses: role in viral life cycle and cell transformation. J Cell Physiol (2008) 1.02

Human cancer-associated mutations in the Aα subunit of protein phosphatase 2A increase lung cancer incidence in Aα knock-in and knockout mice. Mol Cell Biol (2011) 1.00

Dual Role of p53 in Innate Antiviral Immunity. Viruses (2010) 0.91

The critical protein interactions and structures that elicit growth deregulation in cancer and viral replication. Wiley Interdiscip Rev Syst Biol Med (2010) 0.88

Comparisons between murine polyomavirus and Simian virus 40 show significant differences in small T antigen function. J Virol (2011) 0.87

A genetic variant in a PP2A regulatory subunit encoded by the PPP2R2B gene associates with altered breast cancer risk and recurrence. Int J Cancer (2011) 0.83

Polyoma small T antigen triggers cell death via mitotic catastrophe. Oncogene (2014) 0.79

Role of "oncogenic nexus" of CIP2A in breast oncogenesis: how does it work? Am J Cancer Res (2015) 0.77

Neoplastic transformation of porcine mammary epithelial cells in vitro and tumor formation in vivo. BMC Cancer (2015) 0.77

Expression of the small T antigen of Lymphotropic Papovavirus is sufficient to transform primary mouse embryo fibroblasts. Virology (2015) 0.77

The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell (1990) 20.60

Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J (2001) 9.40

Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell (1982) 9.27

ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell (1998) 8.99

The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell (1998) 8.33

The RB and p53 pathways in cancer. Cancer Cell (2002) 8.02

Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A. Cell (1990) 6.12

Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A (1998) 5.74

Principles of tumor suppression. Cell (2004) 5.52

A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J (1991) 5.39

The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol (2001) 4.83

Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol (2002) 4.77

Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J (1999) 4.69

The roles of individual polyoma virus early proteins in oncogenic transformation. Nature (1982) 4.57

Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem Sci (1999) 4.42

Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature (1992) 4.36

The ARF/p53 pathway. Curr Opin Genet Dev (2000) 4.13

Association of protein phosphatase 2A with polyoma virus medium tumor antigen. Proc Natl Acad Sci U S A (1990) 3.76

The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev (1999) 3.50

Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell (2004) 3.29

The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J (1992) 2.97

Control of protein phosphatase 2A by simian virus 40 small-t antigen. Mol Cell Biol (1991) 2.80

Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus. Nat Cell Biol (2001) 2.66

Protein phosphatase 2A: the Trojan Horse of cellular signaling. Cell Signal (2001) 2.48

Regulation of p53 levels by the E1B 55-kilodalton protein and E4orf6 in adenovirus-infected cells. J Virol (1997) 2.09

Posttranslational modification of MDM2. Mol Cancer Res (2003) 1.97

Protein phosphatase 2A: variety of forms and diversity of functions. Acta Biochim Pol (2001) 1.74

The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells. Oncogene (1998) 1.66

Regulation of p53 function. Exp Cell Res (2001) 1.55

Medium tumor antigen of polyomavirus transformation-defective mutant NG59 is associated with 73-kilodalton heat shock protein. J Virol (1987) 1.43

Type 2A protein phosphatase, the complex regulator of numerous signaling pathways. Biochem Pharmacol (2000) 1.43

Targeted degradation of the retinoblastoma protein by human papillomavirus E7-E6 fusion proteins. EMBO J (1992) 1.43

ARF function does not require p53 stabilization or Mdm2 relocalization. Mol Cell Biol (2002) 1.39

T-antigen expression by polyoma mutants with modified RNA splicing. EMBO J (1983) 1.39

Identification of regions in polyomavirus middle T and small t antigens important for association with protein phosphatase 2A. J Virol (1995) 1.34

SV40 T antigen abrogates p53-mediated transcriptional activity. Oncogene (1993) 1.31

Cell transformation by the middle T-antigen of polyoma virus. Oncogene (2001) 1.31

The p21(WAF1/CIP1) promoter is methylated in Rat-1 cells: stable restoration of p53-dependent p21(WAF1/CIP1) expression after transfection of a genomic clone containing the p21(WAF1/CIP1) gene. Mol Cell Biol (2000) 1.23

Regulation by tumour antigens defines a role for PP2A in signal transduction. Semin Cancer Biol (1995) 1.17

Characterization of the Aalpha and Abeta subunit isoforms of protein phosphatase 2A: differences in expression, subunit interaction, and evolution. Biochem J (2003) 1.09

Abrogation of p53-mediated transactivation by SV40 large T antigen. Oncogene (1993) 1.06

The polyoma virus oncogenes. Coordinated functions of three distinct proteins in the transformation of rodent cells in culture. Biochim Biophys Acta (1984) 1.06

The cellular proteins which can associate specifically with polyomavirus middle T antigen in human 293 cells include the major human 70-kilodalton heat shock proteins. J Virol (1989) 0.99

Association between src-kinases and the polyoma virus oncogene middle T-antigen requires PP2A and a specific sequence motif. Oncogene (1999) 0.93

Polyoma virus disrupts ARF signaling to p53. Oncogene (2001) 0.88

p53 in polyoma virus transformed REF52 cells. Oncogene (1997) 0.86

Cell alterations induced by the large T-antigens of SV40 and polyoma virus. Semin Cancer Biol (1990) 0.84

Intrasteric regulation of MDM2. Trends Biochem Sci (2003) 0.80

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36

The RB and p53 pathways in cancer. Cancer Cell (2002) 8.02

Chromosome aberrations in solid tumors. Nat Genet (2003) 7.01

Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev (2003) 4.89

Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell (2003) 4.32

High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res (2005) 3.98

Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science (2006) 3.96

Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res (2009) 3.14

Ras signaling and therapies. Adv Cancer Res (2009) 2.93

Leukocyte adhesion deficiency-III is caused by mutations in KINDLIN3 affecting integrin activation. Nat Med (2009) 2.51

Therapeutic strategies for targeting ras proteins. Genes Cancer (2011) 2.45

Combinatorial patterns of somatic gene mutations in cancer. FASEB J (2008) 2.40

Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer (2004) 2.32

A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell (2005) 2.27

Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol Cell Biol (2004) 2.27

Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst (2007) 2.23

PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Cancer Res (2008) 2.20

SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A (2003) 2.12

Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res (2004) 2.09

Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene (2005) 2.06

Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell (2004) 2.05

A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PLoS One (2006) 2.05

Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell (2005) 1.96

Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene (2003) 1.93

Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene (2004) 1.93

RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Cancer Cell (2013) 1.89

The molecular pathology of cancer. Nat Rev Clin Oncol (2010) 1.86

Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell (2013) 1.73

Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin. Cancer Res (2003) 1.70

A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity. Mol Cell (2006) 1.68

EGFR signals to mTOR through PKC and independently of Akt in glioma. Sci Signal (2009) 1.66

An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res (2004) 1.64

Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov (2012) 1.62

Tpr directly binds to Mad1 and Mad2 and is important for the Mad1-Mad2-mediated mitotic spindle checkpoint. Genes Dev (2008) 1.59

Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. PLoS One (2007) 1.56

A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia (2004) 1.54

Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene (2004) 1.52

Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. Cancer Res (2002) 1.50

Adenoviral proteins mimic nutrient/growth signals to activate the mTOR pathway for viral replication. EMBO J (2005) 1.47

Skp2 suppresses p53-dependent apoptosis by inhibiting p300. Mol Cell (2008) 1.45

DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight. Nucleic Acids Res (2008) 1.42

Tumor suppressor p16INK4a determines sensitivity of human cells to transformation by cooperating cellular oncogenes. Cancer Cell (2003) 1.38

Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A (2010) 1.36

Biallelic mutations in p16(INK4a) confer resistance to Ras- and Ets-induced senescence in human diploid fibroblasts. Mol Cell Biol (2002) 1.36

Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell (2010) 1.35

A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1. Genes Dev (2012) 1.33

p97/DAP5 is a ribosome-associated factor that facilitates protein synthesis and cell proliferation by modulating the synthesis of cell cycle proteins. EMBO J (2006) 1.28

Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling. Proc Natl Acad Sci U S A (2013) 1.27

Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation. Cancer Discov (2013) 1.22

Inhibition of Wnt-1 signaling induces apoptosis in beta-catenin-deficient mesothelioma cells. Cancer Res (2004) 1.22

Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells. Cancer Res (2003) 1.21

Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis. Oncogene (2005) 1.20

Healing full-thickness cartilage defects using adipose-derived stem cells. Tissue Eng (2007) 1.19

Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell (2002) 1.18

Surgeons' attitudes are associated with reoperation and readmission rates. Clin Orthop Relat Res (2015) 1.17

Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res (2006) 1.15

What effects have resident work-hour changes had on education, quality of life, and safety? A systematic review. Clin Orthop Relat Res (2015) 1.13

Polyoma and SV40 proteins differentially regulate PP2A to activate distinct cellular signaling pathways involved in growth control. Proc Natl Acad Sci U S A (2006) 1.12

Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. PLoS One (2012) 1.11

Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells. Cancer Res (2005) 1.11

Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies. Am J Med Genet C Semin Med Genet (2011) 1.10

Killing time for cancer cells. Nat Rev Cancer (2005) 1.08

Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther (2002) 1.07

Cloning and characterization of a functional promoter of the human SOCS-3 gene. Biochem Biophys Res Commun (2003) 1.07

MDMX inhibits the p300/CBP-mediated acetylation of p53. DNA Cell Biol (2002) 1.06

The IKZF3 (Aiolos) transcription factor is highly upregulated and inversely correlated with clinical progression in chronic lymphocytic leukaemia. Br J Haematol (2008) 1.03

The RasGAP proteins Ira2 and neurofibromin are negatively regulated by Gpb1 in yeast and ETEA in humans. Mol Cell Biol (2010) 1.03

War wounds: lessons learned from Operation Iraqi Freedom. Plast Reconstr Surg (2008) 1.03

Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther (2005) 1.03

Phosphorylation of p16INK4A correlates with Cdk4 association. J Biol Chem (2003) 1.00

Cloning and characterization of the promoter of human Wnt inhibitory factor-1. Biochem Biophys Res Commun (2004) 0.99

Downregulation of Skp2 and p27/Kip1 synergistically induces apoptosis in T98G glioblastoma cells. J Mol Med (Berl) (2004) 0.98

Mad2 inhibits the mitotic kinesin MKlp2. J Cell Biol (2010) 0.97

Oncolytic adenoviruses as antiglioma agents. Expert Rev Anticancer Ther (2006) 0.97

Patient safety climate among orthopaedic surgery residents. J Bone Joint Surg Am (2011) 0.96

Surgical management of complex proximal humerus fractures-a systematic review of 92 studies including 4500 patients. J Orthop Trauma (2015) 0.96

Adenovirus overrides cellular checkpoints for protein translation. Cell Cycle (2005) 0.94

Molecular aspects, clinical aspects and possible treatment modalities for Costello syndrome: Proceedings from the 1st International Costello Syndrome Research Symposium 2007. Am J Med Genet A (2008) 0.93

Modulation of the ARF-p53 pathway by the small DNA tumor viruses. Cell Cycle (2005) 0.92

Wnt-1 signal as a potential cancer therapeutic target. Drug News Perspect (2006) 0.92

Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options. Hum Mol Genet (2007) 0.91

Critical role for arginine methylation in adenovirus-infected cells. J Virol (2007) 0.90

A prospective analysis of 179 type 2 superior labrum anterior and posterior repairs: outcomes and factors associated with success and failure. Am J Sports Med (2013) 0.90

Replication-selective viruses for cancer therapy. J Mol Med (Berl) (2001) 0.90

Genomic alterations in human mesothelioma including high resolution mapping of common regions of DNA loss in chromosome arm 6q. Anticancer Res (2003) 0.88

What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiers. Am J Med Genet A (2010) 0.88

Cancer: survival pathways meet their end. Nature (2004) 0.85

Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors. Cancer Res (2014) 0.85

RalGDS comes of age. Cancer Cell (2005) 0.84

Integrin alphavbeta5 is a primary receptor for adenovirus in CAR-negative cells. Virol J (2010) 0.84

The posterolateral portal: optimizing anchor placement and labral repair at the inferior glenoid. Arthrosc Tech (2013) 0.83

Arthroscopic T-capsulotomy for excision of pigmented villonodular synovitis in the hip. Orthopedics (2015) 0.82

MC1R and cAMP signaling inhibit cdc25B activity and delay cell cycle progression in melanoma cells. Proc Natl Acad Sci U S A (2013) 0.81

An analysis of capsular area in patients with anterior, posterior, and multidirectional shoulder instability. Am J Sports Med (2008) 0.81

CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies. Am J Med Genet A (2014) 0.81

High CD49d protein and mRNA expression predicts poor outcome in chronic lymphocytic leukemia. Clin Immunol (2009) 0.81

Characterization of interactions between ras family GTPases and their effectors. Methods Enzymol (2006) 0.80

Endoscopic repair of a gluteus medius tear at the musculotendinous junction. Arthrosc Tech (2013) 0.79

Phosphorylation-independent stabilization of p27kip1 by the phosphoinositide 3-kinase pathway in glioblastoma cells. J Biol Chem (2004) 0.78